Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial.
Spehner L, Orillard E, Falcoz A, Lepiller Q, Bouard A, Almotlak H, Kim S, Curtit E, Meynard G, Jary M, Nardin C, Asgarov K, Abdeljaoued S, Chartral U, Mougey V, Ben Khelil M, Lopez M, Loyon R, Vernerey D, Adotevi O, Borg C, Mansi L, Kroemer M. Spehner L, et al. Among authors: curtit e. BMJ Oncol. 2023 Dec 14;2(1):e000054. doi: 10.1136/bmjonc-2023-000054. eCollection 2023. BMJ Oncol. 2023. PMID: 39886486 Free PMC article.
[EGFR/HER1: a target life].
Viel E, Curtit E, Mansi L, Vignot S. Viel E, et al. Among authors: curtit e. Bull Cancer. 2012 Feb 1;99(2):181-9. doi: 10.1684/bdc.2011.1385. Bull Cancer. 2012. PMID: 21684835 Review. French.
[Targeting the RAS signalling pathway in cancer].
Mansi L, Viel E, Curtit E, Medioni J, Le Tourneau C. Mansi L, et al. Among authors: curtit e. Bull Cancer. 2011 Oct;98(9):1019-28. doi: 10.1684/bdc.2011.1380. Bull Cancer. 2011. PMID: 21715253 Review. French.
Specific anticancer treatments in the last 3 months of life: a French experience.
Viel E, Chaigneau L, Fanton E, Kalbacher E, Thiery-Vuillemnin A, Villanueva C, Dobi E, Curtit E, Almotlak H, Aubry R, Pivot X. Viel E, et al. Among authors: curtit e. Support Care Cancer. 2013 Feb;21(2):405-12. doi: 10.1007/s00520-012-1529-1. Epub 2012 Jun 27. Support Care Cancer. 2013. PMID: 22736464
Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels.
Kim S, Dobi E, Jary M, Monnien F, Curtit E, Nguyen T, Lakkis Z, Heyd B, Fratte S, Cléau D, Lamfichekh N, Nerich V, Guiu B, Demarchi M, Borg C. Kim S, et al. Among authors: curtit e. BMC Cancer. 2013 Dec 27;13:611. doi: 10.1186/1471-2407-13-611. BMC Cancer. 2013. PMID: 24373251 Free PMC article. Clinical Trial.
[Efficacy, safety and cost of eribulin in patients with metastatic breast cancer].
Paillard MJ, Curtit E, Dobi E, Mansi L, Bazan F, Villanueva C, Chaigneau L, Montcuquet P, Meneveau N, Thiery-Vuillemin A, Nerich V, Pivot X. Paillard MJ, et al. Among authors: curtit e. Bull Cancer. 2015 Sep;102(9):737-48. doi: 10.1016/j.bulcan.2015.03.021. Epub 2015 May 26. Bull Cancer. 2015. PMID: 26022285 French.
Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity.
Beziaud L, Mansi L, Ravel P, Marie-Joseph EL, Laheurte C, Rangan L, Bonnefoy F, Pallandre JR, Boullerot L, Gamonet C, Vrecko S, Queiroz L, Maurina T, Mouillet G, Hon TN, Curtit E, Royer B, Gaugler B, Bayry J, Tartour E, Thiery-Vuillemin A, Pivot X, Borg C, Godet Y, Adotévi O. Beziaud L, et al. Among authors: curtit e. Cancer Res. 2016 Jul 15;76(14):4100-12. doi: 10.1158/0008-5472.CAN-15-2452. Epub 2016 May 17. Cancer Res. 2016. PMID: 27197194
56 results